Xilio Therapeutics(XLO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 "In the first quarter, we presented encouraging initial Phase 2 data for vilastobart, our tumor-activated anti- CTLA-4, in combination with atezolizumab in patients with late-line MSS CRC. These data included a preliminary 27% objective response rate in late-line MSS CRC patients without liver metastases accompanied by a differentiated safety profile with a low incidence of colitis and other immune-related adverse events, which are common dose-limiting adverse events for other CTLA-4 agents," s ...